Blog

Rodrigo Sánchez-Bayona: RWE study of ovarian cancer patients treated with PARP inhibitors at ESMO Gynaecological Cancers Congress 2024

Photo from Rodrigo Sánchez-Bayona/X

Jul 1, 2024, 13:29

Rodrigo Sánchez-Bayona: RWE study of ovarian cancer patients treated with PARP inhibitors at ESMO Gynaecological Cancers Congress 2024

Rodrigo Sánchez-Bayona, Medical Oncologist specialising in breast and gynecological cancers at 12 de Octubre University Hospital, posted on X:

“Thanks to The European Society for Medical Oncology for the Merit Travel Grant to present our RWE study of ovarian cancer patients treated with PARP inhibitors in Spain, a young oncologist collaborative research, in ESMO Gynaecological Cancers Congress 2024.”

Source: Rodrigo Sánchez-Bayona/X

cancer ESMO Gynaecological Cancers Congress 2024 Merit Travel Grant OncoDaily Oncology Ovarian Cancer PARP inhibitors Rodrigo Sánchez-Bayona RWE study The European Society for Medical Oncology

Esophageal Cancer: Symptoms, Causes, Stages, Diagnosis & Treatment

Faster, Flexible and Affordable: Mikhail Groubman on Building a Global Legacy in Clinical Research in an Untapped Market

Invest in Health Policy: A Conversation with Professor Andreas Charalambous

FDA Approves Cosibelimab-ipdl for Treatment of Metastatic or Locally Advanced Cutaneous Squamous Cell Carcinoma

Dolph Lundgren’s Fight for Life: How He Survived Kidney Cancer After 9 Years of Battle

Special Coverage